SCHEMBL5218287

SCHEMBL5218287

O=C1OCN(C(=O)OCc2ccccc2)[C@H]1CCCO

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.62
PSEN1 P49768 1/20 0.47
PSEN2 P49810 1/20 0.47
APH1B Q8WW43 1/20 0.47
NCSTN Q92542 1/20 0.47
APH1A Q96BI3 1/20 0.47
PSENEN Q9NZ42 1/20 0.47
F2 P00734 2/20 0.43
ELANE P08246 2/20 0.43
CTSG P08311 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TMEM97 Q5BJF2 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
HTR2C P28335 1/20 0.41
PREP P48147 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5218306 1.00 USP2 (0.62) USP2PSEN1PSEN2APH1BNCSTN
SCHEMBL5711402 0.89 USP2 (0.61) USP2PSEN1PSEN2APH1BNCSTN
SCHEMBL5711279 0.89 USP2 (0.61) USP2PSEN1PSEN2APH1BNCSTN
SCHEMBL7361266 0.88 USP2 (0.60) USP2PSEN1PSEN2APH1BNCSTN
SCHEMBL5711333 0.88 USP2 (0.60) USP2PSEN1PSEN2APH1BNCSTN
SCHEMBL6965437 0.88 USP2 (0.64) USP2PSEN1PSEN2APH1BNCSTN
SCHEMBL5324841 0.87 USP2 (0.59) USP2PSEN1PSEN2APH1BNCSTN
SCHEMBL5711222 0.87 USP2 (0.61) USP2PSEN1PSEN2APH1BNCSTN
SCHEMBL5711176 0.87 USP2 (0.59) USP2PSEN1PSEN2APH1BNCSTN
SCHEMBL5711344 0.87 USP2 (0.61) USP2PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100280120-A1 COMPOUND INDUCING ANGIOGENESIS RESPONSE IN ISCHAEMIC TISSUES Green Cross Therapeutics Private Limited (IN) 2010-11-04 US disclosed
EP-1575900-A4 N-METHYL AMINO ACIDS UBIQUITOUS TECHNOLOGIES PTY LT (AU) 2007-02-21 EP disclosed
US-20050245432-A1 N-methyl amino acids UBIQUITOUS TECHNOLOGIES PTY. LTD. (AU) 2005-11-03 US disclosed
EP-1575900-A1 N-METHYL AMINO ACIDS UBIQUITOUS TECHNOLOGIES PTY LTD (AU) 2005-09-21 EP disclosed
WO-2004007427-A1 N-METHYL AMINO ACIDS UBIQUITOUS TECHNOLOGIES PTY LTD (AU) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245432-A1 N-methyl amino acids VIP, NPPA, PTMS USP2 1849/4885PSEN1 565/4885PSEN2 422/4885
US-20100280120-A1 COMPOUND INDUCING ANGIOGENESIS RESPONSE IN ISCHAEMIC TISSUES FLT4, TEK, VEGFA USP2 4602/4885PSEN1 4783/4885PSEN2 4758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.